Table of Contents
1 Report Prologue
2 Market Introduction
2.1 Introduction
2.2 Scope of Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
6. Asia Pacific Skin Cancer Market, by Type
6.1 Introduction
6.2 Basal Cell Carcinoma
6.2.1 Market Estimates & Forecast, 2020-2027
6.3 Squamous-Cell Carcinoma
6.3.1 Market Estimates & Forecast, 2020-2027
6.4 Melanoma
6.4.1 Market Estimates & Forecast, 2020-2027
7. Asia Pacific Skin Cancer Market, by Treatment
7.1 Introduction
7.2 Non-Invasive Treatments
7.2.1 Market Estimates & Forecast, 2020-2027
7.3 Chemotherapy
7.3.1 Market Estimates & Forecast, 2020-2027
7.4 Surgical
7.4.1 Market Estimates & Forecast, 2020-2027
7.5 Others
8. Asia Pacific Skin Cancer Market, by End user
8.1 Introduction
8.2 Hospital and Clinics
8.2.1 Market Estimates & Forecast, 2020-2027
8.3 Diagnostic Centres
8.3.1 Market Estimates & Forecast, 2020-2027
8.4 Cancer Research Institute
8.4.1 Market Estimates & Forecast, 2020-2027
8.5 Others
9. Asia Pacific Skin Cancer Market, by Region
9.1 Introduction
9.2 Asia Pacific
9.2.1 Australia
9.2.2 Japan
9.2.3 China
9.2.4 India
9.2.5 Republic of Korea
9.2.6 Rest of Asia Pacific
10 Competitive Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
11 Company Profiles
11.1 F. Hoffmann-La Roche Ltd
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Novartis International AG
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Sun Pharma Industries Ltd.
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Elekta AB
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Varian Medical Systems Inc
11.5.1 Company Overview
11.5.2 Product/Business Segment Overview
11.5.3 Financial Overview
11.5.4 Key Development
11.5.5 SWOT Analysis
11.6 Eli Lilly and Co.
11.6.1 Company Overview
11.6.2 Product/Business Segment Overview
11.6.3 Financial Overview
11.6.4 Key Development
11.6.5 SWOT Analysis
11.7 Bristol Myers Squibb
11.7.1 Company Overview
11.7.2 Product/Business Segment Overview
11.7.3 Financial Overview
11.7.4 Key Development
11.7.5 SWOT Analysis
11.8 Leo Pharma A/S
11.8.1 Company Overview
11.8.2 Product/Business Segment Overview
11.8.3 Financial Overview
11.8.4 Key Development
11.8.5 SWOT Analysis
11.9 Others
12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEOโs View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Pharmaceutical Industry
13 Appendix
LIST OF TABLES
Table 1 Skin Cancer Industry Synopsis, 2020-2027
Table 2 Asia Pacific Skin Cancer Market Estimates and Forecast, 2020-2027, (USD Million)
Table 3 Asia Pacific Skin Cancer Market by Country, 2020-2027, (USD Million)
Table 4 Asia Pacific Skin Cancer Market by Types, 2020-2027, (USD Million)
Table 5 Asia Pacific Skin Cancer Market by Treatment, 2020-2027, (USD Million)
Table 7 Asia Pacific Skin Cancer Market by End Users, 2020-2027, (USD Million)
Table 8 Australia Skin Cancer Market by Types, 2020-2027, (USD Million)
Table 9 Australia Skin Cancer Market by Treatment, 2020-2027, (USD Million)
Table 10 Australia Skin Cancer Market by End Users, 2020-2027, (USD Million)
Table 11 Japan Skin Cancer Market by Types, 2020-2027, (USD Million)
Table 12 Japan Skin Cancer Market by Treatment, 2020-2027, (USD Million)
Table 13 Japan Skin Cancer Market by End Users, 2020-2027, (USD Million)
Table 14 China Skin Cancer Market by Types, 2020-2027, (USD Million)
Table 15 China Skin Cancer Market by Treatment, 2020-2027, (USD Million)
Table 16 China Skin Cancer Market by End Users, 2020-2027, (USD Million)
Table 17 India Skin Cancer Market by Types, 2020-2027, (USD Million)
Table 18 India Skin Cancer Market by Treatment, 2020-2027, (USD Million)
Table 19 India Skin Cancer Market by End Users, 2020-2027, (USD Million)
Table 20 Republic of Korea Skin Cancer Market by Types, 2020-2027, (USD Million)
Table 21 Republic of Korea Skin Cancer Market by Treatment, 2020-2027, (USD Million)
Table 22 Republic of Korea Skin Cancer Market by End Users, 2020-2027, (USD Million)
Table 23 Rest of Asia Pacific Skin Cancer Market by Types, 2020-2027, (USD Million)
Table 24 Rest of Asia Pacific Skin Cancer Market by Treatment, 2020-2027, (USD Million)
Table 25 Rest of Asia Pacific Skin Cancer Market by End Users, 2020-2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Asia Pacific Skin Cancer Market
Figure 3 Segmentation Market Dynamics for Skin Cancer Market
Figure 4 Asia Pacific Skin Cancer Market Share, by Types 2020
Figure 5 Asia Pacific Skin Cancer Market Share, by Treatment 2020
Figure 6 Asia Pacific Skin Cancer Market Share, by End Users, 2020
Figure 7 Asia Pacific Skin Cancer Market Share, by Region, 2020
Figure 8 Asia Pacific Skin Cancer Market: Company Share Analysis, 2020 (%)
Figure 9 F. Hoffmann-La Roche Ltd: Key Financials
Figure 10 F. Hoffmann-La Roche Ltd: Segmental Revenue
Figure 11 F. Hoffmann-La Roche Ltd: Geographical Revenue
Figure 12 Novartis International AG: Key Financials
Figure 13 Novartis International AG: Segmental Revenue
Figure 14 Novartis International AG: Geographical Revenue
Figure 15 Sun Pharma Industries Ltd.: Key Financials
Figure 16 Sun Pharma Industries Ltd.: Segmental Revenue
Figure 17 Sun Pharma Industries Ltd.: Geographical Revenue
Figure 18 Elekta AB: Key Financials
Figure 19 Elekta AB: Segmental Revenue
Figure 20 Elekta AB: Geographical Revenue
Figure 21 Varian Medical Systems Inc: Key Financials
Figure 22 Varian Medical Systems Inc: Segmental Revenue
Figure 23 Varian Medical Systems Inc: Geographical Revenue
Figure 24 Eli Lilly and Co.: Key Financials
Figure 25 Eli Lilly and Co.: Segmental Revenue
Figure 26 Eli Lilly and Co.: Geographical Revenue
Figure 27 Bristol Myers Squibb: Key Financials
Figure 28 Bristol Myers Squibb: Segmental Revenue
Figure 29 Bristol Myers Squibb: Geographical Revenue
Figure 30 Leo Pharma A/S: Key Financials
Figure 31 Leo Pharma A/S: Segmental Revenue
Figure 32 Leo Pharma A/S: Geographical Revenue